SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced the appointment of Dr. Krishna Bhat, MD, Ph.D., FACC, an experienced bioscientist and cardiologist, to serve on its advisory board as a chief medical advisor. According to the update, Dr. Bhat has a practice of over 35 years in the field of clinical and interventional cardiology. He is also a recipient of the 2021 Hall of Fame Award from the American Heart Association and the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada. “We are delighted to have Dr. Bhat join our advisory board,” said Baron Night, SOHM president and CEO. “Dr. Bhat brings valuable experience and expertise in the field of cardiology, which will support our planned acquisition of ABBIE Technology and its innovative patents, clinical trials, diagnostic kits and cardiac treatments. Dr. Bhat is a renowned clinical and interventional cardiologist who has authored over 16 medical scientific publications. We look forward to benefiting from his insights and guidance for our current and future pipelines.”
To view the full press release, visit https://ibn.fm/geNli
About SOHM, Inc.
SOHM is a growing generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that aims to build continuous growth. SOHM manufacturing and marketing targets rapidly growing healthcare segments such as nutraceuticals, cosmeceuticals and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India and strategic alliances with U.S. manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America and Southeast Asia. To learn more about the company, visit www.SOHM.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
